Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
The optimal use of bexarotene in cutaneous T-cell lymphoma
also known as HA-1077
Following a 30 mg/kg subcutaneous injection to Lewis rats
the parent drug is a poor inhibitor of COX-2 byproducts
InChi: InChI=1S/C18H15Cl2N3O2/c1-9-16(10(2)23-22-9)11-7-13(19)17(14(20)8-11)21-15-6-4-3-5-12(15)18(24)25/h3-8
MK-1064 R501 The optimal use of bexaroteneMK 1064 is a selective orexin 2 receptor antagonist (2 SORA) for the research of insomnia. target: 2 SORA In vivo: MK 1064 promotes sleep and increases both rapid eye movement (REM) and non REM (NREM) sleep in rats at OX2R occupancies higher than the range observed for dual orexin receptor antagonists. MK 1064 increases NREM and REM sleep in dogs without inducing cataplexy. The reference for animal administration is 30 mg kg. Product information CAS
US$ 138.55
US$ 421.32
US$ 196.98
US$ 148.88
US$ 138.55
US$ 268.44